SPY771.31QQQ722.25BTC/USD83,538.70+0.72%DIA526.68GLD379.32TLT80.33
Benzinga

William Blair

William Blair is a global investment banking and asset management firm based in Chicago, Illinois. Founded in 1935, the company offers services including mergers and acquisitions advisory, equity research, institutional sales and trading, and private wealth management. It serves corporate, institutional, and individual clients, with a focus on delivering strategic financial solutions and long-term investment strategies.

William Blair Recent News

Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge
Corbus reports FDA alignment on the CRB-701 path, as analysts flag upside tied to the head and neck cancer opportunity and obesity pipeline.
10x Genomics Seen As Key Player In AI-Driven Biological Data Buildout
10x Genomics Seen As Key Player In AI-Driven Biological Data Buildout
William Blair upgrades 10x Genomics, citing AI-driven data demand, improving execution and Xenium validation as key growth drivers.
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capricor, Moderna, and raising hopes for smoother drug approvals.
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results and safety concerns that raised doubts about the drug's commercial future.
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
Amgen says its MariTide obesity drug helped patients maintain weight loss for a second year, with good safety and fewer side effects.
Why uniQure Stock Is Trading Lower After FDA Meeting Update
Why uniQure Stock Is Trading Lower After FDA Meeting Update
The gene therapy company received final meeting minutes from the FDA regarding a pre-Biologics License Application for AMT-130
Intuitive Surgical Q3 Results Ease Bear Market Concerns, Analyst Views 'Headwinds As Largely Noise'
Intuitive Surgical Q3 Results Ease Bear Market Concerns, Analyst Views 'Headwinds As Largely Noise'
Intuitive Surgical crushes Q3 earnings with $2.51 billion revenue, a 23% jump, fueled by $2.40 EPS and 20% growth in da Vinci procedures.
Thermo Fisher's Upbeat Earnings Suggest Worst Is Over For Scientific Tools Sector, Analyst Says
Thermo Fisher's Upbeat Earnings Suggest Worst Is Over For Scientific Tools Sector, Analyst Says
Thermo Fisher Scientific reports Q3 2025 adjusted earnings of $5.79 per share, sales of $11.12 billion and raised its full-year guidance.
FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate
FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate
FDA extends review of Denali Therapeutics' tividenofusp alfa for Hunter syndrome to April 2026; analysts remain confident in its approval prospects.
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.
What's Going On With Viking Therapeutics Stock On Wednesday?
What's Going On With Viking Therapeutics Stock On Wednesday?
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand
Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders
Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource allocation and challenges.
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth
Repligen Q3 earnings beat expectations with $0.43 EPS and $154.87 million in sales. The company raises 2024 EPS guidance and reports strong growth in CDMO and equipment.
Carvana's Q4 Earnings Impress Analysts, Shares Surge On Strong Profit Outlook
Carvana's Q4 Earnings Impress Analysts, Shares Surge On Strong Profit Outlook
Shares of Carvana Co (NYSE: CVNA) were climbing in early trading on Friday, after the company reported its fourth-quarter results.
Block Re-Focuses On Cash App, 8 Analysts Provide Their Takeaways From Q4 Results
Block Re-Focuses On Cash App, 8 Analysts Provide Their Takeaways From Q4 Results
Block Inc (NYSE: SQ) Thursday reported its fourth-quarter results and issued full-year guidance.
Twilio Reports Upbeat Q4 Earnings, But Investors Pull Back: What 7 Wall Street Analysts Are Saying
Twilio Reports Upbeat Q4 Earnings, But Investors Pull Back: What 7 Wall Street Analysts Are Saying
Twilio Inc (NYSE: TWLO) shares tanked in early trading on Thursday, even after the company reported upbeat results for its fourth quarter.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved